Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer

Keyphrases

• Tumor 100%
• Cisplatin 100%
• Doxorubicin 100%
• Methotrexate 100%
• Vinblastine 100%
• Bladder Cancer 100%
• Lymph Node Positive 100%
• Neoadjuvant 100%
• Complete Response 60%
• Improved Survival 40%
• Partial Response 40%
• Lymph Node Status 40%
• Partial Responder 40%
• Positive Lymph Nodes 40%
• Tumor Status 40%
• Postchemotherapy Surgery 40%
• Chemotherapy 20%
• Primary Tumor 20%
• Progression-free Survival 20%
• Prognostic Value 20%
• In(III) 20%
• Response to Chemotherapy 20%
• 5-year Survival 20%
• Long-term Development 20%
• Residual Disease 20%
• Non-invasive Method 20%
• Objective Response 20%
• Progressive Disease 20%
• Neoadjuvant Chemotherapy 20%
• Lymph Node 20%
• Response Evaluation 20%
• Resection Specimen 20%
• Bladder 20%
• Post-chemotherapy 20%
• Long-term Clinical Outcome 20%
• Lymph Node Dissection 20%
• Negative Lymph Nodes 20%
• Bladder Tumor 20%
• Complete Responders 20%
• Aspiration Cytology 20%
• No Tumors 20%
• Node Positive 20%
• Bladder Diseases 20%
• Subsequent Surgery 20%

Medicine and Dentistry

• Cisplatin 100%
• Doxorubicin 100%
• Bladder Cancer 100%
• Methotrexate 100%
• Lymph Node 100%
• Vinblastine 100%
• Neoplasm 85%
• Chemotherapy 57%
• Primary Tumor 14%
• Minimal Residual Disease 14%
• Progression Free Survival 14%
• Bladder 14%
• Progressive Disease 14%
• Neoadjuvant Chemotherapy 14%
• Lymph Node Biopsy 14%
• Retroperitoneal Lymph Node Dissection 14%
• Non Invasive Procedure 14%
• Cancer Chemotherapy 14%
• Bladder Tumor 14%
• Bladder Disease 14%
• Aspiration Cytology 14%